...
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb
    • Gloperba
    • Expanded Access Policy
  • Partners
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • Publications
    • SEC Filings
    • Governance
    • Analyst Coverage
    • FAQs
    • Contact IR
    • Stock
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
  • View Our Pipeline
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb
    • Gloperba
    • Expanded Access Policy
  • Partners
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • Publications
    • SEC Filings
    • Governance
    • Analyst Coverage
    • FAQs
    • Contact IR
    • Stock
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
  • View Our Pipeline
close

Blog

Home » SEC FIlings »
06 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 6, 2023
  • Posted by Ulisses
  • Twitter
  • Email
  • LinkedIn
  • Twitter
  • Email
  • LinkedIn
Previous Post
Next Post
Close
Recent Posts
  • test according
    March 1, 2024 No Comments
  • Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
    January 8, 2024 No Comments
  • Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information
    January 2, 2024 No Comments
  • Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without
    December 26, 2023 No Comments
  • Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists
    December 20, 2023 No Comments

scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Twitter
  • Email
  • LinkedIn

©2024 Scilex Holding All Rights Reserved SCI-00075
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info
Seraphinite AcceleratorOptimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.